Reactions Weekly

, Volume 1220, Issue 1, pp 14–15 | Cite as

Human papillomavirus vaccine recombinant quadrivalent

First report of anaphylaxis: 10 case reports
Case report
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death

  • life-threatening

  • hospitalisation

  • disability

  • congenital anomaly

  • requires intervention to prevent permanent impairment or damage

First published case report

In a retrospective study, eight female patients aged 15 to 25 years experienced anaphylaxis after receiving the human papillomavirus vaccine recombinant quadrivalent [dosages not stated]. All patients subsequently recovered. A further two girls aged 11 and 12 years developed anaphylactic symptoms which could not be confirmed as anaphylaxis according to the Brighton definition.

A 15-year-old girl received one dose of the human papillomavirus vaccine recombinant quadrivalent [Gardasil]. Less than 5 minutes later, she experienced injection site pain, an urticarial rash on her face, neck and chest, and a generalised prickle sensation. There was a sensation of throat closure, cough, dyspnoea, difficulty talking, a tight, painful chest and wheeziness. She was...


Salbutamol Angioedema Chest Tightness Injection Site Pain Urticarial Rash 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Brotherton JML, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S, New South Wales Health HPV Adverse Events Panel.Anaphylaxis following quadrivalent human papillomavirus vaccination. Canadian Medical Association Journal 179: 525-533, No. 6, 9 Sep 2008 - AustraliaGoogle Scholar

Copyright information

© Adis International limited or Adis Data Information BV 2008

Personalised recommendations